Does Anti-RNA Polymerase III Increase Cancer Risk?

Testing positive for the anti-RNA Polymerase III antibody means you have a statistically higher risk of developing cancer around the same time your scleroderma symptoms begin ^[1][2][3]. Because of this connection, doctors often recommend comprehensive cancer screenings to ensure that any potential hidden malignancy is found and treated as early as possible ^[4][5].

What is a “Synchronous Malignancy”?

When a doctor talks about a synchronous malignancy, they are referring to a cancer that develops at roughly the same time as another condition ^[6]. For people with the anti-RNA Polymerase III antibody, cancer and scleroderma sometimes appear within a short window of time, typically within one to three years of each other ^[6][7][8].

This close timing is often called a paraneoplastic phenomenon ^[9][10]. Researchers believe that the immune system detects a developing tumor and produces anti-RNA Polymerase III antibodies to fight it ^[9][10]. However, these antibodies mistakenly cross-react and attack the body’s own healthy tissues, triggering the rapid onset of scleroderma symptoms ^[9][10].

Understanding the Cancer Risk

If you test positive for the anti-RNA Polymerase III antibody, research shows you have an approximately 48% higher relative risk of developing cancer compared to scleroderma patients who do not have this specific antibody ^[1][2][3]. However, it is crucial to understand that a “48% higher relative risk” does not mean you have a 48% chance of getting cancer. Scleroderma itself is rare, and the overall absolute risk is relatively low. The vast majority of people who test positive for this antibody do not have a synchronous cancer.

Furthermore, this elevated risk is primarily tied to that “short window” around the onset of your scleroderma symptoms ^[6][7][8]. After the first few years pass without a cancer diagnosis, your risk generally returns closer to the baseline.

This increased risk is not tied to just one specific type of rare cancer. Studies have reported a variety of malignancies associated with this antibody, including:

• Breast cancer ^[11][7]
• Lung cancer ^[12]
• Skin cancer ^[12]
• Hematological (blood) disorders ^[13]

Because many of these are also among the most common cancers in the general population, maintaining your standard, routine cancer screenings is incredibly important ^[4].

The Importance of Comprehensive Screening

Currently, there are no rigid, universally established guidelines for the exact imaging or tests required for anti-RNA Polymerase III-positive patients ^[14][10]. However, rheumatologists and oncologists generally agree on a strategy of heightened vigilance during the first few years of your diagnosis ^[4][5].

Your doctor’s recommendation for comprehensive screening will likely include:

• Routine Age-Appropriate Screenings: Ensuring you are up-to-date on standard tests like mammograms, colonoscopies, and Pap smears ^[4].
• Targeted Imaging and Tests: Depending on your specific symptoms and medical history, your doctor may order additional tests, such as CT scans or specific blood tests, to look for hidden cancers ^[4][5]. Doctors carefully balance the necessity of these scans against potential concerns like radiation exposure.

Symptoms to Watch For at Home

Between screenings, it is helpful to monitor yourself for potential warning signs. Be sure to report any of the following to your doctor:

• Unexplained, unintended weight loss
• New lumps or bumps
• Severe, unexplained fatigue
• A very rapid and severe worsening of your skin thickening (which is sometimes associated with paraneoplastic scleroderma) ^[15][3]

Finding and treating an underlying cancer early is crucial for your overall health. Additionally, some clinical reports suggest that successfully treating an underlying cancer might lead to improvements in scleroderma-related symptoms ^[16].

This is undoubtedly an overwhelming situation, but these screenings are a proactive tool to protect your health. Working closely with both your rheumatologist and an oncologist will ensure you have an expert care team monitoring you during the highest-risk window.